Document is current
Any future updates will be listed below
-
Authors
Jakob, D.
Dannehl, D.
Endres, H.
Jansen, L.
Hermann, S.
Hartkopf, A. D.
Huwer, S.
Jung, L.
Thijssen, O.
Juhasz-Böss, I.
Taran, F. A.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 23 July 2025
First Online: 18 August 2025
Declarations
:
: Dorothee Jakob: No conflicts of interest declared. Dominik Dannehl: Honoraria from Gilead, Novartis. DaiichiSankyo, Onkowissen.TV and AstraZeneca. Hannes Endres: no conflicts of interest declared. Lina Jansen: no conflicts of interest declared. Silke Hermann: no conflicts of interest declared. Andreas Hartkopf: grants from Exact Science, Veracyte; Consulting fees from Roche, Novartis, MSD, Agendia, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowissen, Lilly, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Daiichi Sankyo; Honoraria from Roche, Novartis, MSD, Agendia, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowissen, Lilly, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Daiichi Sankyo, Seagen, Eisai, Thieme, Springer, Veracyte Travel/meeting fees from Roche, Novartis, Lilly, AstraZeneca, GSK, ExactScience, Gileasd, Menarini Stemline, Pfizer, Daiichi Sankyo Participation on a Data Safety Monitoring Board or Advisory Board of Novartis, Roche, Agendia, Lilly, Gilead, AstraZeneca, Pfizer, MSD, Daiichi Sankyo, GSK, Menarini Stemline, ExactScience, Eisai, Sandoz/Hexal. Sarah Huwer: no conflicts of interest declared. Lisa Jung: no conflicts of interest declared. Olivia Thijssen: no conflicts of interest declared. Ingolf Juhasz-Böss: no conflicts of interest declared. Florin-Andrei Taran: consulting fees from AbbVie, AstraZeneca, ImmunoGen, GSK, Novartis, Pfizer, and Roche; Honoraria from AbbVie, AstraZeneca, ImmunoGen, GSK, Novartis, Pfizer, and Roche.
